Dr. Gane is Professor of Medicine at the University of Auckland, New Zealand, Hepatologist and Deputy Director of the New Zealand Liver Unit at Auckland City Hospital. Dr. Gane trained in hepatology and liver transplantation at the Institute of Liver Studies, King’s College School of Medicine, London, where he completed his thesis on pathogenesis of the newly discovered hepatitis C. On his return to New Zealand, Dr Gane set up a dedicated Phase I research centre that led the development of the first oral treatments for hepatitis C. He is now focused on developing a finite cure for hepatitis B. Dr Gane has published over 450 papers in peer-reviewed journals and has received many research awards including the NZHRC Beaven and Liley Medals. Dr Gane is the Ministry of Health’s Advisor for viral hepatitis and chairs the oversight committee for the Hepatitis C Elimination Strategy. He also is clinical advisor for the Hepatitis Foundation of New Zealand HepB surveillance programme.

Professor Bev Lawton (ONZM), nō Ngāti Porou, is the founder/director of Te Tātai Hauora o Hine (the National Centre for Women’s Health Research Aotearoa) at Te Herenga Waka, Victoria University of Wellington. Bev’s significant contribution to advancing Māori health is in the field of cervical cancer prevention. Her advocacy and research in HPV self-testing aims to increase cervical screening uptake for wāhine Māori, and pursues the elimination of cervical cancer amongst wāhine Māori. She was made a Distinguished Fellow of the Royal College of General Practice in 2017. Bev was awarded the Royal Australia and New Zealand College of Obstetricians and Gynaecologists Māori Women’s Health Award in 2020 and won the 2021 Women of Influence Award in the Innovation, Science and Health category. Last year Bev was the recipient of the HRC’s Beaven Medal for excellence in translational health research.

Anh is an infectious disease modeller with current research aimed to develop disease burden estimation and mathematical modelling approaches to inform the surveillance, monitoring and evaluation of progress towards national strategies for the elimination of hepatitis B. Anh has a background in economics with a specialisation in health economics.

Doctor Rachel Sacks-Davis is the Deputy Head of Modelling and Biostatistics at the Burnet Institute. She has more than 10 years experience in viral hepatitis research, with a strong interest in understanding the impact of DAA therapies on hepatitis C epidemiology.